uniQure follow-up AMT-130 Phase I/II data show 80% slowing at 36 months in high-dose patients
uniQure said follow-up Phase I/II results for AMT-130 in Huntington’s extended to 48 months, with high-dose patients showing 80% slowing at 36 months versus an external natural-history comparator; functional benefit was maintained over four years.